Reuters logo
Tranzyme to explore strategic options
February 8, 2013 / 11:30 AM / 5 years ago

Tranzyme to explore strategic options

(Reuters) - Drugmaker Tranzyme Inc said it will explore strategic options, including a sale, less than two months after it stopped the second mid-stage trial of its drug for stomach paralysis.

The company retained Stifel as its financial adviser for the strategic review process, and said it has not made a decision to pursue any specific transaction.

Tranzyme went public in April 2011 at $4 per share and has a market value of $15 million. It has two other products in early testing.

Tranzyme shares closed at 56 cents on Thursday on the Nasdaq.

Reporting by Esha Dey in Bangalore; Editing by Supriya Kurane

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below